The estimated Net Worth of Phillip A Sharp is at least $30.3 Milhão dollars as of 29 February 2024. Phillip Sharp owns over 30,000 units of Alnylam Pharmaceuticals Inc stock worth over $7,857,300 and over the last 21 years he sold ALNY stock worth over $21,935,627. In addition, he makes $495,707 as Independent Director at Alnylam Pharmaceuticals Inc.
Phillip has made over 19 trades of the Alnylam Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of ALNY stock worth $1,777,500 on 29 February 2024.
The largest trade he's ever made was selling 294,100 units of Alnylam Pharmaceuticals Inc stock on 14 May 2004 worth over $17,281,316. On average, Phillip trades about 11,038 units every 93 days since 2003. As of 29 February 2024 he still owns at least 30,000 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Phillip Sharp stock trades at the bottom of the page.
Dr. Phillip A. Sharp Ph.D. is Independent Director of Alnylam Pharmaceuticals, Inc. Dr. Sharp is a scientific founder of Alnylam and has served as a member of our board of directors since June 2002. Dr. Sharp is an Institute Professor at the David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (MIT), and was the Founding Director of the McGovern Institute for Brain Research at MIT. Dr. Sharp has been a professor at MIT since 1974. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Sharp also serves as a director of Syros Pharmaceuticals, Inc. and formerly served as a director of Biogen Inc., which he co-founded in 1978.
As the Independent Director of Alnylam Pharmaceuticals Inc, the total compensation of Phillip Sharp at Alnylam Pharmaceuticals Inc is $495,707. There are 13 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.
Phillip Sharp is 75, he's been the Independent Director of Alnylam Pharmaceuticals Inc since 2002. There are no older and 20 younger executives at Alnylam Pharmaceuticals Inc.
Phillip's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, eKevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: